|
Variate
|
n
a (%)
|
ADAM33Methylation (%)
|
p-value
|
|---|
| | |
Positive
|
Negative
| |
|---|
|
Tumor Stage
| | | | |
|
0/I
|
14 (20.0)
|
4 (28.6)
|
10 (71.4)
|
0.641
|
|
II
|
33 (47.1)
|
14 (42.4)
|
19 (57.6)
| |
|
III/IV
|
23 (32.9)
|
8 (34.8)
|
15 (65.2)
| |
|
Tumor Size
b
| | | | |
|
pT1/pTis
|
20 (27.4)
|
6 (30.0)
|
14 (70.0)
|
0.174
|
|
pT2
|
38 (52.1)
|
14 (36.8)
|
24 (63.2)
| |
|
pT3/pT4
|
15 (20.5)
|
9 (60.0)
|
6 (40.0)
| |
|
Histological Grade (SBR)
| | | | |
|
I
|
19 (27.1)
|
8 (42.1)
|
11 (57.9)
|
0.799
|
|
II
|
33 (47.1)
|
14 (42.4)
|
19 (57.6)
| |
|
III
|
18 (25.7)
|
6 (33.3)
|
12 (66.7)
| |
|
Lymph Node Status
| | | | |
|
Negative
|
34 (47.9)
|
13 (38.2)
|
21 (61.8)
|
0.965
|
|
Positive
|
37 (52.1)
|
15 (40.5)
|
22 (59.5)
| |
|
Estrogen Receptor Status (ER)
| | | | |
|
Negative
|
12 (17.1)
|
4 (33.3)
|
8 (66.7)
|
0.751
|
|
Positive
|
58 (82.9)
|
24 (41.4)
|
34 (58.6)
| |
|
ERBB2 Status
| | | | |
|
Negative
|
43 (66.2)
|
18 (41.9)
|
25 (58.1)
|
0.378
|
|
Positive
|
22 (33.8)
|
6 (27.3)
|
16 (72.7)
| |
|
Progesterone Receptor Status (PR)
| | | | |
|
Negative
|
15 (24.6)
|
4 (26.7)
|
11 (73.3)
|
0.678
|
|
Positive
|
46 (75.4)
|
17 (36.9)
|
29 (63.1)
| |
|
Metastasis Status
| | | | |
|
Negative
|
55 (79.7)
|
23 (41.8)
|
32 (58.2)
|
0.548
|
|
Positive
|
14 (20.3)
|
4 (28.6)
|
10 (71.4)
| |
|
Recurrence Status
| | | | |
|
Negative
|
63 (91.3)
|
23 (36.5)
|
40 (63.5)
|
0.201
|
|
Positive
|
6 (8.7)
|
4 (66.7)
|
2 (33.3)
| |
|
Histological Tumor Type
| | | | |
|
Invasive Ductal Carcinoma
|
51 (70.8)
|
13 (25.5)
|
38 (74.5)
|
0.0002
|
|
Invasive Lobular Carcinoma
|
21 (29.2)
|
16 (76.2)
|
5 (23.8)
| |
-
aOnly female patients with primary invasive breast cancer were included. bAccording to TNM classification [10].
